J. Kellogg Parsons, MD, MHS, FACS, presented “Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery” during the Perspectives in Urology: Point Counterpoint 2020 virtual conference in November 2020.
How to cite: Parsons, J. Kellogg. “Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery” November 2020. Accessed Oct 2021. https://dev.grandroundsinurology.com/men-with-high-risk-prostate-cancer-should-not-undergo-neoadjuvant-therapy-prior-to-surgery/
Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery – Summary:
J. Kellogg Parsons MD, MHS, FACS, Professor of Urology at the University of California, San Diego, explains why neoadjuvant therapy prior to surgery may not be the best option for prostate cancer patients. He reviews findings from definitive randomized clinical trials that show ADT does not improve survival, and addresses common side effects, such as cognitive impairment and loss of testosterone function. Dr. Parsons then explains AUA Clinical Guidelines published in alignment with SUO and ASTRO that strongly recommend against routine neoadjuvant therapy prior to surgery. Lastly, he gives examples of when physicians can consider the option despite such caveats.
The pro perspective of this point-counterpoint series by Robert E. Reiter, MD, was published last week on GRU.
About the Perspectives in Urology: Point Counterpoint 2020 virtual conference:
Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, as well as Program Co-Chair Dan Theodorescu, MD, PhD, this virtual conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This two-day interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking. A focus on prostate cancer was given on Wednesday, November 11th, with a focus on bladder cancer given on Thursday, November 12th.